Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary - Takeaways - MDSpire

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

  • By

  • Shruti K. Gohil

  • Taliser R. Avery

  • Ken Kleinman

  • Edward Septimus

  • Amarah Mauricio

  • Kenneth E. Sands

  • Neha Varma

  • Selsebil Sljivo

  • Kaleb Roemer

  • William S. Cooper

  • Russell E. Poland

  • Robert A. Weinstein

  • Samir M. Fakhry

  • Jeffrey Guy

  • Julia Moody

  • Micaela H. Coady

  • Kim N. Smith-Sells

  • Mary K. Hayden

  • David W. Kubiak

  • Chenette Burks

  • Richard Platt

  • Susan S. Huang

  • Meghan A. Baker

  • June 10, 2026

  • 0 min

Share

  • 1

    Empiric extended-spectrum antibiotics are often prescribed for hospitalized cancer patients, despite many being safely treated with standard-spectrum antibiotics.

  • 2

    An antibiotic stewardship bundle with real-time CPOE prompts significantly reduced extended-spectrum antibiotic use in non-critically ill patients.

  • 3

    Cancer patients may be at higher risk for infections and complications, leading to increased use of extended-spectrum antibiotics due to diagnostic uncertainty.

  • 4

    The INSPIRE trials included cancer patients and evaluated interventions to optimize initial antibiotic selection rather than just de-escalation.

  • 5

    The CPOE prompts recommended standard-spectrum antibiotics for patients with less than 10% risk of multidrug-resistant organisms based on electronic health records.

Original Source(s)

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

  • by Shruti K. Gohil, Taliser R. Avery, Ken Kleinman, Edward Septimus, Amarah Mauricio, Kenneth E. Sands, Neha Varma, Selsebil Sljivo, Kaleb Roemer, William S. Cooper, Russell E. Poland, Robert A. Weinstein, Samir M. Fakhry, Jeffrey Guy, Julia Moody, Micaela H. Coady, Kim N. Smith-Sells, Mary K. Hayden, David W. Kubiak, Chenette Burks, Richard Platt, Susan S. Huang, Meghan A. Baker

  • June 10, 2026

Related Content

Clinical utility of an optoelectronic imaging tracing system for diagnosis of high-grade cervical lesions

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma